Appendix B. Sources of Evidence
1. The following documentation and opinion was made available to the Committee:
a. Assessment Report:
-
prepared by Wessex Institute for Health Research and Development, University of Southampton (The effectiveness and cost effectiveness of temozolomide for the treatment of recurrent malignant glioma, November 2000).
b. Manufacturer/sponsor submissions:
-
Schering Plough UK Ltd
c. Professional/specialist group, patient/carer group and trade association submissions:
-
Royal College of Physicians and the Royal College of Radiologists (joint)
-
MRC Clinical Trials Unit
-
Royal College of General Practitioners
-
Royal College of Surgeons of England
-
Association of British Neurologists and the Royal College of Physicians (joint)
d. External expert and patient advocate submissions:
-
Dr Paul Symonds, Reader and Consultant in Clinical Oncology, University of Leicester
-
Douglas Guerrero, Clinical Nurse Specialist/Neuro‑Oncology, Royal Marsden Hospital
-
Dr Mike Brada, Reader and Consultant in Clinical Oncology, Royal Marsden Hospital